The Dana Foundation   Report issue

Foundation Phase 2 Phase 4
Founded: New York NY United States (1950)

Organization Overview

First Clinical Trial
1999
NCT00002154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Atherosclerosis (Phase 4)

Brain Concussion (Phase 2)

Carotid Artery Diseases (Phase 4)

Cocaine-Related Disorders (Phase 2)

Cognition Disorders (Phase 2)

Dementia (Phase 2)

Disease (Phase 4)

Heart Diseases (Phase 2)

Hypoplastic Left Heart Syndrome (Phase 2)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Transposition of Great Vessels (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 14